Vivoryon Therapeutics N.V. (AMS:VVY)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
1.724
-0.138 (-7.41%)
Apr 3, 2025, 2:09 PM CET
229.01%
Market Cap 48.54M
Revenue (ttm) -3.62M
Net Income (ttm) -31.19M
Shares Out 26.07M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 116,601
Average Volume 42,682
Open 1.810
Previous Close 1.862
Day's Range 1.652 - 1.836
52-Week Range 0.410 - 6.300
Beta 1.96
RSI 23.84
Earnings Date Apr 24, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 15
Stock Exchange Euronext Amsterdam
Ticker Symbol VVY
Full Company Profile

Financial Performance

Financial Statements

News

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Challenges

4 months ago - GuruFocus

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

4 months ago - GuruFocus